Recent events
Recent events tied to this brand in public sources.
Back to profile7 entries
2026
ExoCordOA consortium launches osteoarthritis therapy project
Exogenus Therapeutics-led ExoCordOA announced a five-year Horizon Europe-funded project to advance extracellular vesicle-enriched secretome therapies toward clinical use, initially focusing on osteoarthritis. The ten-member consortium secured $14.4 million to support the work.
2022
MilliporeSigma announces acquisition of Lonza's MAST platform
MilliporeSigma announced that it had acquired Lonza's MAST platform; the release states that the platform will become part of MilliporeSigma upon closing the deal.
2021
Moderna and Lonza announce additional European vaccine production capacity
Moderna announced an additional agreement with Lonza to establish a production line at Lonza’s Geleen site in the Netherlands, planned to support an additional 300 million doses per year if the vaccine candidate is authorized.
2021
Altimmune expands AdCOVID manufacturing collaboration with Lonza
Altimmune announced an expansion of its manufacturing collaboration with Lonza. Under the expanded agreement, Lonza will commission a dedicated manufacturing suite at its facility near Houston for clinical and commercial production of Altimmune's AdCOVID vaccine candidate.
2020
Synbiotech and Lonza partner to promote TWK10
Synbiotech partnered with Lonza to promote its TWK10 probiotic ingredient in the United States, Canada, Europe and Brazil. Lonza will promote the ingredient to brand companies and work on a formula incorporating it with other ingredients.
2020
Moderna and Lonza announce vaccine manufacturing collaboration
Moderna and Lonza announced a 10-year collaboration under which Lonza will establish manufacturing sites in the United States and Switzerland for Moderna’s experimental coronavirus vaccine, subject to regulatory approval.
2019
Lonza and DiNAQOR announce gene therapy collaboration
Lonza and DiNAQOR announced a strategic collaboration to advance DiNAQOR's preclinical programs for MYBPC3 cardiomyopathies. Lonza will provide production support for the DiNA-001 program, with product supply handled at its Houston facility.